Recent advances in the treatment of testicular cancer

References

• Cancer Research Campaign. Testicular Cancer – UK. Factsheet16(1), 1–6 (1998).
   Google Scholar
• International Germ Cell Consensus Classification. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J. Clin. Oncol.15(2), 594–603 (1997).
   PubMed Web of Science ®Google Scholar
• Peckham MJ. Investigations and staging: general aspects and staging classification. In: The Management of Testicular Tumors. Edward Arnold, London, UK, 89–101 (1971).
   Google Scholar
• Huddart R, Norman A, Coward D et al. The health of long-term survivors of testicular cancer. Proc. Am. Soc. Clin. Oncol.331a (2000) (Abstract 1301).
   Google Scholar
• O’Sullivan JM, Huddart RA, Norman AR, Nicholls J, Dearnaley DP, Horwich A. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumors. Ann. Oncol.14(1), 91–96 (2003).
   PubMed Web of Science ®Google Scholar
• Cook A, Dzik-Jurasz A, Padhani A, Norman A, Huddart R. The prevalence of avascular necrosis in patients treated with chemotherapy for testicular tumors. Br. J. Cancer85(11), 1624–1626 (2001).
   PubMed Web of Science ®Google Scholar
• Lampe H, Horwich A, Norman A, Nicholls J, Dearnaley DP. Fertility after chemotherapy for testicular germ cell cancers. J. Clin. Oncol.15(1), 239–45 (1997).
   PubMed Web of Science ®Google Scholar
• De Santis M, Albrecht W, Holtl W, Pont J. Impact of cytotoxic treatment on long-term fertility in patients with germ-cell cancer. Int. J. Cancer83(6), 864–865 (1999).
   PubMed Web of Science ®Google Scholar
• Travis L, Curtis R, Storm H et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J. Natl Cancer Inst.89(19), 1429–1439 (1997).
   PubMed Web of Science ®Google Scholar
• Fossa SD, Aass N, Harvei S, Tretli S. Increased mortality rates in young and middle-aged patients with malignant germ cell tumors. Br. J. Cancer90(3), 607–12 (2004).
   PubMed Web of Science ®Google Scholar
• Zagars GK, Ballo MT, Lee AK, Strom SS. Mortality after cure of testicular seminoma. J. Clin. Oncol.22(4), 640–647 (2004).
   PubMed Web of Science ®Google Scholar
• Huddart R, Norman A, Shahidi M et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J. Clin. Oncol.21(18), 1513–1523 (2003).
   PubMed Web of Science ®Google Scholar
• Meinardi M, Gietema J, van der Graaf W et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J. Clin. Oncol.18(8), 1725–1732 (2000).
   PubMed Web of Science ®Google Scholar
• Cullen MH, Stenning SP, Parkinson MC et al. Short-course adjuvant chemotherapy in high-risk Stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J. Clin. Oncol.14(4), 1106–1113 (1996).
   PubMed Web of Science ®Google Scholar
• Read G, Stenning SP, Cullen MH et al. Medical Research Council prospective study of surveillance for Stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J. Clin. Oncol.10(11), 1762–68 (1992).
   PubMed Web of Science ®Google Scholar
• Sweeney C, Hermans B, Heilman D, Foster R, Donohue J, Einhorn L. Results and outcome of retroperitoneal lymph node node dissection for clinical Stage I embryonal carcinoma-predominant testis cancer. J. Clin. Oncol.18(2), 358–362 (2000).
   PubMed Web of Science ®Google Scholar
• Moynihan CM. Testicular cancer: the psychosocial problems of patients and their relatives. Cancer Surveys6(3), 477–510 (1987).
   PubMedGoogle Scholar
• Heidenreich A, Sesterhenn I, Moul J. Prognostic risk factors in low Stage testicular germ cell tumors. Cancer79(9), 1641–1645 (1997).
   PubMed Web of Science ®Google Scholar
• Vergouwe Y, Steyerberg E, Eijkemans M, Albers P, Habbema J. Predictors of occult metastasis in clinical Stage I nonseminoma: a systematic review. J. Clin. Oncol.21(22), 4092–4099 (2003).
   PubMed Web of Science ®Google Scholar
• Lassen U, Daugaard G, Eigtved A, Hojgaard L, Damgaard K, Rorth M. Whole-body FDG-PET in patients with Stage I non-seminomatous germ cell tumors. Eur. J. Nucl. Med. Mol. Imaging30(3), 396–402 (2003).
   PubMed Web of Science ®Google Scholar
• Hart, Wall. Radiation Exposure of the UK Population from Medical and Dental X-ray Examination. National Radiological Protection Board, Oxfordshire, UK, NRPB-W4 (2002).
   Google Scholar
• Harvey M, Geldart T, Duell R, Mead G, Tung K. Routine computerised tomographic scans of the thorax in surveillance of Stage I testicular non-seminomatous germ-cell cancer – a necessary risk? Ann. Oncol.13, 237–242 (2002).
   PubMed Web of Science ®Google Scholar
• Anzai Y, Piccoli CW, Outwater EK et al. Evaluation of neck and body metastases to nodes with ferumoxtran 10-enhanced MR imaging: Phase III safety and efficacy study. Radiology228(3), 777–788 (2003).
   PubMed Web of Science ®Google Scholar
• Clinical Oncology Information Network (CION) Guidelines Guidelines on the management of adult testicular cancer. J. Clin. Oncol.12(5), S173–S210 (2000).
   Google Scholar
• Fosså SD, Horwich A, Russell J et al. Optimal planning target volume for Stage I testicular seminoma: a Medical Research Council randomized trial. J. Clin. Oncol.17(4), 1146–1154 (1999).
   PubMed Web of Science ®Google Scholar
• Peckham MJ, Barrett A, Liew K et al. The treatment of metastatic germ-cell testicular tumors with bleomycin, etoposide and cisplatin (BEP). Br. J. Cancer47(5), 613–619 (1983).
   PubMed Web of Science ®Google Scholar
• Jones W, Fossa S, Meas G et al. A randomized trial of two radiotherapy schedules in the adjuvant of Stage I seminoma (MRC TE18) – preliminary report. In: Germ Cell Tumors V. Springer, Berlin, Germany, 235–236 (2002).
   Google Scholar
• Livsey JE, Taylor B, Mobarek N, Cooper RA, Carrington B, Logue JP. Patterns of relapse following radiotherapy for Stage I seminoma of the testis: implications for follow-up. Clin. Oncol. (R. Coll. Radiol.)13(4), 296–300 (2001).
   PubMed Web of Science ®Google Scholar
• Horwich A. Surveillance for Stage I seminoma of the testis. In: Testicular Cancer Clinical Investigation and Management. Chapman and Hall Medical, London, UK, Chapter 7, 109–116 (1991).
   Google Scholar
• Bayley A, Warde P, Milosevic M, Goospodarowicz M. Surveillance for Stage I testicular seminoma. Urol. Oncol.6(4), 139–143 (2001).
   PubMed Web of Science ®Google Scholar
• Warde P, Specht L, Horwich A et al. Prognostic factors for relapse in Stage I seminoma managed by surveillance: a pooled analysis. J. Clin. Oncol.20(22), 4448–4452 (2002).
   PubMed Web of Science ®Google Scholar
• Oliver RTD, Edmonds PM, Ong JYH et al. Pilot studies of 2 and 1 course carboplatin as adjuvant for Stage I seminoma: should it be tested in a randomized trial against radiotherapy? Int. J. Radiat. Oncol. Biol. Phys.29(1), 3–8 (1994).
   PubMed Web of Science ®Google Scholar
• Dieckmann KP, Bruggeboes B, Pichlmeier U, Kuster J, Mullerleile U, Bartels H. Adjuvant treatment of clinical Stage I seminoma: is a single course of carboplatin sufficient? Urology55(1), 102–106 (2000).
   PubMed Web of Science ®Google Scholar
• Oliver R, Mason M, Von der Masse H et al. A randomized comparison of single agent carboplatin with radiotherapy in the adjuvant treatment of Stage I seminoma of the testis, following orchidectomy: MRC TE19/EORTC 30982. Proc. Am. Soc. Clin. Oncol.22 (2004) (Abstract 4517).
   Google Scholar
• Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated germ-cell tumors: with cisplatin, bleomycin, and either vinblastine or etoposide. N. Engl. J. Med.316(23), 1435–1440 (1987).
   Google Scholar
• Bokemeyer C, Kohrmann O, Tischler J et al. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with ‘good-risk’ metastatic non-seminomatous germ cell tumors. Ann. Oncol.7(10), 1015–1021 (1996).
   PubMed Web of Science ®Google Scholar
• Horwich A, Sleijfer DT, Fossa SD et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J. Clin. Oncol.15(5), 1844–1852 (1997).
   PubMed Web of Science ®Google Scholar
• Bajorin DF, Sarosdy MF, Pfister DG et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multi-institutional study. J. Clin. Oncol.11(4), 598–606 (1993).
   PubMed Web of Science ®Google Scholar
• Simpson A, Paul J, Graham J, Kaye S. Fatal bleomycin pulmonary toxicity in the west of Scotland 1991–1995: a review of patients with germ cell tumors. Br. J. Cancer78(8), 1061–1066 (1998).
   PubMed Web of Science ®Google Scholar
• Levi J, Raghaven D, Harvey V et al. The importance of bleomycin in combination chemotherapy for good prognosis germ cell carcinoma. J. Clin. Oncol.11(7), 1300–1305 (1993).
   PubMed Web of Science ®Google Scholar
• Bosl GJ, Geller N, Bajorin D et al. A randomized trial of etoposide + cisplatin versus VAB-6 (vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin) in patients with good prognosis germ cell tumor. J. Clin. Oncol.6(8), 1231–1238 (1988).
   PubMed Web of Science ®Google Scholar
• de Wit R, Stoter G, Kaye SB et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular non-seminoma: a randomized study of the European Organisation for Research and Treatment of Cancer Genitourinary Tract Cancer Co-operative Group. J. Clin. Oncol.15(5), 1837–1843 (1997).
   PubMed Web of Science ®Google Scholar
• Loehrer PJ, Johnson D, Elson P, Einhorn LH, Trump D. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Co-operative Oncology Group Trial. J. Clin. Oncol.13(2), 470–476 (1995).
   PubMed Web of Science ®Google Scholar
• Boublikova L, Oliver R, Shamash J et al. Bleomycin in combination chemotherapy of testicular or extragonadal germ cell tumors: a review of published trials. In: Germ Cell Tumors V. Harnden P, Joffe K, Jones W (Eds), Springer-Verlag, London, UK, 244–246 (2002).
   Google Scholar
• de Wit R, Roberts J, Wilkinson P, de Mulder P et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Co-operative Group and the Medical Research Council. J. Clin. Oncol.19(6), 1629–1640 (2001).
   PubMed Web of Science ®Google Scholar
• Saxman B, Finch D, Gonin R, Eihnorn LH. Long-term follow-up of a Phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ cell tumors: the Indiana University Experience. J. Clin. Oncol.16, 702–706 (1998).
   PubMed Web of Science ®Google Scholar
• Sonneveld D, Hoekstra H, van de Graaf W et al. Improved long-term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era. Cancer91(7), 1304–1315 (2001).
   PubMed Web of Science ®Google Scholar
• Aass N, Klepp O, Cavallin Stahl E et al. Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience. J. Clin. Oncol.9(5), 818–826 (1991).
   PubMed Web of Science ®Google Scholar
• Harding MJ, Paul J, Gillis CR, Kaye SB. Management of malignant teratoma: does referral to a specialist unit matter? Lancet314(8851), 999–1002 (1993).
   Google Scholar
• Collette L, Sylvester R, Stenning S et al. Impact of the treating institution on survival of patients with ‘poor-prognosis’ metastatic nonseminoma. J. Natl Cancer Inst.91(10), 839–846 (1999).
   PubMedGoogle Scholar
• Kaye SB, Mead GM, Fossa S et al. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J. Clin. Oncol.16(2), 692–701 (1998).
   PubMed Web of Science ®Google Scholar
• Nichols CR, Catalano PJ, Crawford ED, Vogelzang NJ, Einhorn LH, Loehrer PJ. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Co-operative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J. Clin. Oncol.16(4), 1287–1293 (1998).
   PubMed Web of Science ®Google Scholar
• Bower M, Newlands E, Holden L, Rustin G, Begent R. Treatment of men with metastatic non-seminomatous germ cell tumors with cyclical POMB/ACE chemotherapy. Ann. Oncol.8(5), 477–483 (1997).
   PubMed Web of Science ®Google Scholar
• Bhala N, Coleman JM, Radstone CR et al. The management and survival of patients with advanced germ-cell tumors: improving outcome in intermediate and poor prognosis patients. Clin. Oncol. (R. Coll. Radiol.)16(1), 40–7 (2004).
   PubMed Web of Science ®Google Scholar
• Droz JP, Culine S, Bouzy J et al. Preliminary results of a randomized trial comparing bleomycin, etoposide, cisplatin (BEP) and cyclophosphamide, doxorubicin, cisplatin/vinblastin, bleomycin (CISCA/VB) for patients (pts) with intermediate- and poor-risk metastatic non-seminomatous germ-cell tumors (NSGCT). Proc. Am. Soc. Clin. Oncol.173a (2001) (Abstract 690).
   Google Scholar
• Chevreau C, Droz JP, Pico JL et al. Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumors. Eur. Urol.23(1), 213–218 (1993).
   PubMed Web of Science ®Google Scholar
• Schmoll HJ, Kollmannsberger C, Metzner B et al. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended Phase I/II study of the German Testicular Cancer Study Group. J. Clin. Oncol.21(22), 4083–4091 (2003).
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Kollmannsberger C, Meisner C et al. First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: a multivariate and matched-pair analysis. J. Clin. Oncol.17(11), 3450–3456 (1999).
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Harstrick A, Beyer J et al. The use of dose-intensified chemotherapy in the treatment of metastatic non-seminomatous testicular germ cell tumors. Semin. Oncol.25(2 Suppl. 4), 24–32 (1998).
   PubMed Web of Science ®Google Scholar
• Price P, Hogan SJ, Horwich A. The growth rate of metastatic non-seminomatous germ cell testicular tumors measured by marker production doubling time-I. Theoretical basis and practical application. Eur. J. Cancer26(4), 450–453 (1990).
   PubMed Web of Science ®Google Scholar
• Davis A, Tannock I. Repopulation of tumor cells between cycles of chemotherapy: a neglected factor. Lancet Oncol.1, 86–93 (2000).
   PubMedGoogle Scholar
• Dearnaley DP. Intensive induction chemotherapy for poor risk tumors. In: Testicular Cancer – Investigation and Management. 2nd edition. Horwich A (Ed.), Chapman and Hall Medical, London, UK, 271–285 (1996).
   Google Scholar
• Wettlaufer JN, Feiner AS, Robinson WA. Vincristine, cisplatin, and bleomycin with surgery in the management of advanced metastatic nonseminomatous testis tumors. Cancer53, 203–209 (1984).
   PubMed Web of Science ®Google Scholar
• Samuels ML, Holoye PY, Johnson DE. Bleomycin combination chemotherapy in the management of testicular neoplasia. Cancer36, 318–326 (1975).
   PubMed Web of Science ®Google Scholar
• Gerson R, Tellez BE, Lazaro LM et al. Low toxicity with continuous infusion of high-dose bleomycin in poor prognostic testicular cancer. Am J. Clin. Oncol.16(4), 323–326 (1993).
   PubMed Web of Science ®Google Scholar
• Christian JA, Huddart RA, Norman A et al. Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors. J. Clin. Oncol.21(5), 871–877 (2003).
   PubMed Web of Science ®Google Scholar
• Fizazi K, Prow DM, Do KA et al. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumors. Br. J. Cancer86(10), 1555–1560 (2002).
   PubMed Web of Science ®Google Scholar
• van Dijk MR, Steyerberg EW, Stenning SP, Habbema JD. Identifying subgroups among poor prognosis patients with nonseminomatous germ cell cancer by tree modelling: a validation study. Ann. Oncol.15(9), 1400–1405 (2004).
   PubMed Web of Science ®Google Scholar
• Fizazi K, Culine S, Kramar A et al. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J. Clin. Oncol.22(19), 3868–3876 (2004).
   PubMed Web of Science ®Google Scholar
• Stevens MJ, Norman AR, Dearnaley DP, Horwich A. Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma. J. Clin. Oncol.13(1), 87–92 (1995).
   PubMed Web of Science ®Google Scholar
• de Wit R, Sylvester R, Tsitsa C et al. Tumor marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer. Br. J. Cancer75(3), 432–435 (1997).
   PubMed Web of Science ®Google Scholar
• Donohue J, Leviovitch I, Foster R, Baniel J, Tognoni P. Integration of surgery and systemic therapy: results and principles of integration. Semin. Urol. Oncol.16(2), 65–71 (1998).
   PubMedGoogle Scholar
• Gelderman W, Oosterhuis J, Koops H, Oldhoff J, Sleijfer D. Late recurrence of mature teratoma in nonseminomatous testicular tumor after PVB chemotherapy and surgery. Urology33, 10–14 (1989).
   PubMed Web of Science ®Google Scholar
• Hendry W. Decision making in abdominal surgery following chemotherapy for testicular cancer. Eur. J. Cancer31A(5), 649–650 (1995).
   PubMed Web of Science ®Google Scholar
• Logothetis CJ, Samuels ML, Trindale A, Johnson DE. The growing teratoma syndrome. Cancer50, 1629–1635 (1982).
   PubMed Web of Science ®Google Scholar
• Gerl A, Clemm C, Schmeller N, Hentrich M, Lamerz R, Wilmanns W. Late relapse of germ cell tumors after cisplatin-based chemotherapy. Ann. Oncol.8, 41–47 (1997).
   PubMed Web of Science ®Google Scholar
• Shahidi M, Norman A, Nicholls J, Dearnaley D, Horwich A, Huddart R. Late recurrence in 1263 men with testicular germ cell tumors: multivariate analysis of risk factors and implications for management. Cancer95(3), 520–530 (2002).
   PubMed Web of Science ®Google Scholar
• Jones W, Stenning S, Read G et al. Long-term follow-up of unresected residual masses following platinum based chemotherapy for metastatic non-seminoma of the testis (MRC Study TE16): a preliminary report. In: Germ Cell Tumors IV. Jones W, Appleyard I, Harnden P, Joffe J (Eds), John Libbey & Company Ltd, London, UK, 269–275 (1998).
   Google Scholar
• Oldenburg J, Alfsen GC, Lien HH, Aass N, Waehre H, Fossa SD. Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J. Clin. Oncol.21(17), 3310–3317 (2003).
   PubMed Web of Science ®Google Scholar
• Hendry W, Norman A, Dearnaley D et al. Metastatic nonseminomatous germ cell tumors of the testis – results of elective and salvage surgery for patients with residual retroperitoneal masses. Cancer94(6), 1668–1676 (2002).
   PubMed Web of Science ®Google Scholar
• Steyerberg EW, Gerl A, Fossa SD et al. Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer. J. Clin. Oncol.16(1), 269–274 (1998).
   PubMed Web of Science ®Google Scholar
• Vergouwe Y, Steyerberg E, Foster R, Habbema D, Donohue J. Validation of a prediction model and its predictors for the histology of residual masses in nonseminomatous testicular cancer. J. Urol.165(1), 84–88 (2001).
   PubMed Web of Science ®Google Scholar
• Steyerberg EW, Donohue JP, Gerl A et al. Residual masses after chemotherapy for metastatic testicular cancer: the clinical implications of the association between retroperitoneal and pulmonary histology. Re-analysis of Histology in Testicular Cancer (ReHiT) Study Group. J. Urol.158(2), 474–478 (1997).
   PubMed Web of Science ®Google Scholar
• Fizazi K, Tjulandin S, Salvioni R et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy. J. Clin. Oncol.19(10), 2647–2657 (2001).
   PubMed Web of Science ®Google Scholar
• Puc HS, Heelan R, Mazumdar M et al. Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan–Kettering Cancer Center. J. Clin. Oncol.14(2), 454–460 (1996).
   PubMed Web of Science ®Google Scholar
• Duchesne GM, Stenning SP, Aass N et al. Radiotherapy after chemotherapy for metastatic seminoma – a diminishing role. MRC Testicular Tumor Working Party. Eur. J. Cancer33(6), 829–835 (1997).
   PubMed Web of Science ®Google Scholar
• De Santis M, Becherer A, Bokemeyer CS et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J. Clin. Oncol.22(6), 1034–1039 (2004).
   PubMed Web of Science ®Google Scholar
• Fosså S, Stenning S, Gerl A et al. Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumors. Br. J. Cancer80(9), 1392–1399 (1999).
   PubMed Web of Science ®Google Scholar
• McCaffrey J, Mazumdar M, Bajorin D, Bosl G, Vlamis V, Motzer R. Ifosfamide and cisplatin containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J. Clin. Oncol.15(7), 2559–2563 (1997).
   PubMed Web of Science ®Google Scholar
• Loehrer P, Gonin R, Nichols C, Weathers T, Einhorn L. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J. Clin. Oncol.16(7), 2500–2504 (1998).
   PubMed Web of Science ®Google Scholar
• Beyer J, Kramar A, Mandanas R et al. High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J. Clin. Oncol.14(10), 2638–2645 (1996).
   PubMed Web of Science ®Google Scholar
• Horwich A. Salvage therapy of germ cell tumors. Br. J. Cancer71(5), 901–903 (1995).
   PubMed Web of Science ®Google Scholar
• Beyer J, Stenning S, Gerl A, Fossa S, Siegert W. High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matched-pair analysis. Ann. Oncol.13(4), 599–605 (2002).
   PubMed Web of Science ®Google Scholar
• Rosti G, Pico J-L, Wandt H et al. High-dose chemotherapy (HDC) in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumors (GCT); first results of a prospective randomized trial of the European Group for Blood and Marrow Transplantation (EBMT): IT-94 study. Proc. Am. Soc. Clin. Oncol.180a (2002) (Abstract 716).
   Google Scholar
• Motzer RJ, Bajorin DF, Schwartz LH et al. Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J. Clin. Oncol.12(11), 2277–2283 (1994).
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Beyer J, Metzner B et al. Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann. Oncol.7(1), 31–34 (1996).
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Gerl A, Schoffski P et al. Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer. J. Clin. Oncol.17(2), 512–516 (1999).
   PubMed Web of Science ®Google Scholar
• Einhorn L, Stender M, Williams S. Phase II trial of gemcitabine in refractory germ cell tumors. J. Clin. Oncol.17(2), 509–511 (1999).
   PubMed Web of Science ®Google Scholar
• Kollmannsberger C, Rick O, Derigs HG et al. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J. Clin. Oncol.20(8), 2031–2037 (2002).
   PubMed Web of Science ®Google Scholar
• Rick O, Bokemeyer C, Beyer J et al. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer. J. Clin. Oncol.19(1), 81–88 (2001).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Mazumdar M, Sheinfeld J et al. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J. Clin. Oncol.18(6), 1173–1180 (2000).
   PubMed Web of Science ®Google Scholar
• Fosså SD, Kaye SB, Mead GM et al. An MRC/EORTC randomized trial in poor prognosis metastatic teratoma, comparing treatment with/without filgrastim (G-CSF). Proc. Am. Soc. Clin. Oncol.14, 245 (1995).
   Google Scholar
• Bokemeyer C, Schmoll H-J. Secondary neoplasms following treatment of malignant germ cell tumors. J. Clin. Oncol.11(9), 1703–1709 (1993).
   PubMed Web of Science ®Google Scholar
• van Leeuwen FE, Stiggelbout AM, van den Belt-Dusebout AW et al. Second cancer risk following testicular cancer: a follow-up study of 1,909 patients. J. Clin. Oncol.11(3), 415–424 (1993).
   PubMed Web of Science ®Google Scholar
• Hinton S, Catalano PJ, Einhorn LH et al. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial. Cancer97(8), 1869–1875 (2003).
   PubMed Web of Science ®Google Scholar
• Germa-Lluch JR, Garcia del Muro X, Tabernero JM et al. BOMP/EPI intensive alternating chemotherapy for IGCCC poor-prognosis germ-cell tumors: the Spanish Germ-Cell Cancer Group experience (GG). Ann. Oncol.10(3), 289–293 (1999).
   PubMed Web of Science ®Google Scholar
• Puc HS, Bajorin DF, Bosl GJ, Amsterdam A, Motzer RJ. Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors. Invest. New Drugs13(2), 163–165 (1995).
   PubMed Web of Science ®Google Scholar
• Kondagunta GV, Sheinfeld J, Mazumdar M et al. Relapse-free and overall survival in patients with pathologic Stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy. J. Clin. Oncol.22(3), 464–467 (2004).
   PubMed Web of Science ®Google Scholar
• Kollmannsberger C, Gerl A, Schleucher N et al. Phase II study of bendamustine in patients with relapsed or cisplatin-refractory germ cell cancer. Anticancer Drugs11(7), 535–539 (2000).
   PubMed Web of Science ®Google Scholar
• Vuky J, McCaffrey J, Ginsberg M et al. Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors. Invest. New Drugs18(3), 265–267 (2000).
   PubMed Web of Science ®Google Scholar
• Sandler A, Fox S, Meyers T et al. Paclitaxel plus gallium nitrate and filgrastim in patients with refractory malignancies: a Phase I trial. Am. J. Clin. Oncol.21(2), 180–184 (1998).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Sheinfeld J, Mazumdar M J et al. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J. Clin. Oncol.18(12), 2413–2418 (2000).
   PubMed Web of Science ®Google Scholar
• Hinton S, Catalano P, Einhorn LH et al. Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Co-operative Oncology Group. J. Clin. Oncol.20(7), 1859–1863 (2002).
   PubMed Web of Science ®Google Scholar
• Pectasides D, Pectasides M, Farmakis D et al. Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor as third-line treatment in relapsed or cisplatin-refractory germ-cell tumor patients: a Phase II study. Eur. Urol.46(2), 216–221 (2004).
   PubMed Web of Science ®Google Scholar
• Kollmannsberger C, Beyer J, Liersch R et al. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J. Clin. Oncol.22(1), 108–114 (2004).
   PubMed Web of Science ®Google Scholar